IP Library Granted Patent US 7,728,145
Granted Patent B2
US 7,728,145 · App. 10/574,545 · Granted Jun 1, 2010

Industrial method for separation and purification of fentanyl by reverse phase preparative chromatography

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,728,145
App. No.
10/574,545
Granted
Jun 1, 2010
Kind
B2
Abstract

There is described a process for the purification of an impure preparation containing fentanyl by means of a reverse phase preparative chromatography process. A chromatographic column is loaded with a stationary phase, typically a silica particle having an organic ligand bound thereto. With a loading ratio of from about 50 to about 150 the impure preparation is acidified and passed through the column. The column is eluted with typically an aqueous solution of acetonitrile and the purified fentanyl is obtained in a specified cut.

Claims (34)

1. An industrial process for recovering pure fentanyl from an impure aqueous preparation comprising fentanyl containing phenethylpiperaniline, the process comprising:

subjecting said impure aqueous preparation to a reverse-phase high performance preparative liquid column chromatography, the column containing a stationary phase, the stationary phase being bonded-phase silica containing ligands selected from the group consisting of butyl-, octyl- and octadecyl-moieties, the chromatography comprising contacting the column with the aqueous preparation and then eluting the column with a mobile phase comprising an aqueous acidic solution containing an organic solvent, the aqueous mobile phase pH being in the range of from about 2.5 to about 3.5, and

recovering pure fentanyl,

wherein the pure fentanyl comprises a phenethylpiperaniline impurity level of less than about 0.010 weight percent, and further wherein a loading ratio of column media to fentanyl loaded onto the column is in the range of from about 50 to about 150.

2. The process of claim 1 wherein the loading ratio is in the range of from about 70 to about 130.

3. The process of claim 1 wherein the ligand is octyl-silane.

4. The process of claim 1 wherein the acid employed to acidify the aqueous mobile phase is selected from the group consisting of acetic, formic, tartaric, hydrobromic, nitric and hydrochloric acid.

5. The process of claim 1 wherein the pH of the aqueous mobile phase is in the range of from about 2.8 to about 3.2.

6. The process of claim 1 wherein the organic solvent is an alcohol.

7. The process of claim 6 wherein the alcohol is selected from the group consisting of methanol, propanol, isopropanol, butanol and t-butanol.

8. The process of claim 1 wherein the organic solvent is acetonitrile.

9. The process of claim 1 wherein the impure preparation is acidified so as to prepare a fentanyl salt.

10. The process of claim 9 wherein the acid employed to acidify the aqueous solution of fentanyl is an inorganic acid.

11. The process of claim 10 wherein the acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, phosphoric acid, phosphorous acid, sulfuric acid and nitric acid.

12. The process of claim 9 wherein the acid employed to acidify the aqueous solution of fentanyl is an organic acid.

13. The process of claim 12 wherein the organic acid is selected from the group consisting of acetic acid, formic acid, oxalic acid, succinic acid, lactic acid and tartaric acid.

14. The process of claim 9 wherein the pH of the aqueous solution of fentanyl is in the range of from about 2 to about 5.

15. The process of claim 14 wherein the pH of the aqueous solution of fentanyl is in the range of about from about 2.5 to about 3.5.

16. The process of claim 11 wherein the acid is hydrochloric acid.

17. The process of claim 8 wherein the concentration of acetonitrile in the aqueous mobile phase is in the range of from about 2 to about 100 volume percent.

18. The process of claim 8 wherein the concentration of acetonitrile in the aqueous mobile phase is in the range of from about 5 to about 10 volume percent during the collection of the purified fentanyl.

19. A process for purifying an impure preparation of fentanyl containing phenethylpiperaniline which comprises the steps of:

(a) packing a preparative chromatographic column with a reverse-phase chromatographic packing material comprising bonded-phase silica containing ligands selected from the group consisting of butyl-, octyl- and octadecyl-moieties;

(b) passing through said column an aqueous, acidified solution of impure fentanyl at a loading ratio of from about 50 to about 150; and

(c) eluting said column with an aqueous acidic solution of an organic solvent with a pH in the range of from about 2.5 to about 3.5 to produce an eluate containing fentanyl having less than about 0.010 weight percent phenethylpiperaniline.

20. The process of claim 19 wherein the eluate is divided into four cuts wherein:

(i.) a first cut is discarded,

(ii.) a second cut that is combined with a fourth cut wherein the aqueous solution of an organic solvent is reduced and then recycled through the column, and

(iii.) a third cut that contains less than about 0.010 percent phenethylpiperaniline.

21. An industrial process for recovering pure fentanyl from an impure aqueous preparation comprising fentanyl containing phenethylpiperaniline, the process comprising:

acidifying the impure aqueous preparation to prepare a fentanyl salt with a pH in the range of from about 2.5 to about 3.5;

subjecting said impure aqueous preparation to a reverse-phase high performance preparative liquid column chromatography, the column containing a stationary phase, the stationary phase being bonded-phase silica containing ligands with octyl-moieties, the chromatography comprising contacting the column with the aqueous preparation and then eluting the column with a mobile phase comprising an aqueous acidic solution containing an organic solvent, the aqueous mobile phase pH being in the range of from about 2.5 to about 3.5, and

recovering pure fentanyl,

wherein the pure fentanyl comprises a phenethylpiperaniline impurity level of less than about 0.010 weight percent, and further wherein a loading ratio of column media to fentanyl loaded onto the column is in the range of from about 50 to about 150.

Assignments (3)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →
CHANGE OF LEGAL ENTITY Recorded Aug 16, 2011
From: MALLINCKRODT INC.
To: MALLINCKRODT LLC
Reel/Frame 026754/0001 →